Overview

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Status:
Recruiting

Trial end date:
2024-12-02

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

Phase:

Phase 2

Details

Lead Sponsor:

Hoffmann-La Roche
Ignyta, Inc.

Treatments:

Entrectinib